Επίσημη σελίδα
NEJM After randomization, 83 participants were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive placebo. No serious adverse events … Read More
FDA briefing document on Moderna’s vaccine (pdf) … Throughout each stage of clinical testing, the Moderna vaccine proved to be safe and highly effective at preventing symptomatic COVID-19. In a study … Read More
JAMA The first 10 days after COVID-19 discharge appear to be a particularly risky period, according to a JAMA research letter. Researchers studied nearly 1800 COVID-19 patients who were discharged from … Read More
JAMA Question Is administration of systemic corticosteroids associated with reduced 28-day mortality in critically ill patients with coronavirus disease 2019 (COVID-19)? Findings In this prospective meta-analysis of 7 randomized trials that … Read More
NEJM, Dr. Harlan Krumholz, a co-author of this research letter, is also editor-in-chief of NEJM Journal Watch Cardiology. Among U.S. adults aged 25 to 44, there were 19% more deaths … Read More
Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19. The trials are part … Read More
NEJM Group:Interview: Dr. Hanny Al-Samkari and his team examined whether giving therapeutic levels of anticoagulants to critically ill COVID-19 patients soon after admission to the ICU improved survival. He … Read More
The Lancet AstraZeneca vaccine: Findings from the interim analysis of the randomized trials of the AstraZeneca–University of Oxford vaccine have now been published in The Lancet. As previously reported, the adenovirus … Read More
NEJM, Eric J. Rubin, M.D., Ph.D., and Dan L. Longo, M.D. …….. Nevertheless, the trial results are impressive enough to hold up in any conceivable analysis. This is a triumph. … Read More
An FDA advisory committee voted on Thursday that the potential benefits of the Pfizer and BioNTech COVID-19 vaccine outweigh its risks for people ages 16 years and up. The … Read More
